Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 3/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967968 | 0.85 | MEN1 (0.44) | CYP11B1CYP11B2MEN1HCRTR1KMT2A | |
| SCHEMBL749310 | 0.78 | RAB9A (0.47) | MEN1HCRTR1KMT2APDE2APDE10A | |
| SCHEMBL31031662 | 0.78 | MAPT (0.47) | MEN1KMT2APDE2APDE10A | |
| SCHEMBL30621949 | 0.78 | CYP11B1 (0.50) | CYP11B1CYP11B2MEN1HCRTR1KMT2A | |
| SCHEMBL2634929 | 0.78 | SMN1; SMN2 (0.58) | CYP11B1CYP11B2MEN1HCRTR1KMT2A | |
| SCHEMBL28463862 | 0.78 | CYP11B1 (0.50) | CYP11B1CYP11B2MEN1HCRTR1KMT2A | |
| SCHEMBL3967675 | 0.77 | CYP11B1 (0.53) | CYP11B1CYP11B2PDE2APDE10A | |
| SCHEMBL25080560 | 0.76 | CYP11B1 (0.49) | CYP11B1CYP11B2MEN1HCRTR1KMT2A | |
| SCHEMBL13526687 | 0.75 | ACSS2 (0.48) | CYP11B1CYP11B2MEN1HCRTR1KMT2A | |
| SCHEMBL3487680 | 0.74 | CYP11B1 (0.47) | CYP11B1CYP11B2PCSK9ACSS2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | CYP11B1 170/4885CYP11B2 179/4885MEN1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.